Exosomal circPOLK promotes metastasis of NSCLC cells via regulating mir-1204/SOX8 axis.

Yang-Ling Li, Ye-Han Liu, Jing Cheng, Zhen-Qiang Wei, Neng-Ming Lin, Chong Zhang

Abstract read

In one paragraph

Article in Cancer cell international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yang-Ling Li *Department of Clinical Pharmacology, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, 310006, Zhejiang, China.

Ye-Han Liu *School of Medicine, Hangzhou City University, No. 51 Huzhou Street, Hangzhou, 310015, Zhejiang, China.

Jing ChengSchool of Medicine, Hangzhou City University, No. 51 Huzhou Street, Hangzhou, 310015, Zhejiang, China.

Zhen-Qiang WeiDepartment of Cardiothoracic Surgery, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, 310006, China.

Neng-Ming LinDepartment of Clinical Pharmacology, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, 310006, Zhejiang, China. lnm1013@zju.edu.cn.

Chong ZhangSchool of Medicine, Hangzhou City University, No. 51 Huzhou Street, Hangzhou, 310015, Zhejiang, China. zhangchong@hzcu.edu.cn.

Funding

National Natural Science Foundation of China 82273352

6 · The paper itself

Abstract

Non-small cell lung cancer (NSCLC) is the most common subtype of lung cancer, and the prognosis of NSCLC patients is still poor particularly for patients with metastatic disease. Thus, extending the knowledge about the mechanism of metastasis is critical for NSCLC treatment. We demonstrated that hsa_circ_0073052 (circPOLK) was overexpressed in blood exosomes from cancer patients than those from healthy people. CircPOLK overexpression enhanced the metastasis and EMT progression of NSCLC cells. Next, circPOLK might function as miRNA sponge in NSCLC cells. Through bioinformatical prediction and RNA pull-down experiment, miR-1204 might be a potential target of circPOLK. Interestingly, serumal miR-1204 was an efficacious diagnostic and prognostic molecular for lung cancer patients and acted as a suppressor on NSCLC progression. Furthermore, circPOLK promoted metastasis of NSCLC via regulating miR-1204. Furthermore, SOX8 was identified as a potential target of circPOLK/miR-1204. GO enrichment of circPOLK regulated DEGs showed that circPOLK might be involved in angiogenesis of NSCLC. Indeed, circPOLK secreted by NSCLC cells could promote angiogenesis. Our dada not only identifies a novel circPOLK/miR-1204/SOX8 signaling pathway, but also provides therapeutical strategies for NSCLC patients with metastatic disease.

Indexed as

AngiogenesisHsa_circ_0073052MetastasisMiR-1204NSCLCSOX8

Identifiers

PMID42104439

DOI10.1186/s12935-026-04306-2

PMCPMC13374188

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.